CytoMed Therapeutics Ltd (GDTC) AI Dilution Summary

Cash was $1,127,242 at 2026-06-30 against estimated monthly burn of $211,954. The company is funding itself through its active ATM program with R.F. Lafferty & Co., Inc. That program is authorised to $4,304,945 and has sold 99,123 shares for $237,550 since the program began, through 2026-09-30. Sales after 2026-09-30 are not yet reported, so these figures are a floor.